(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials
CNBC Halftime Report Final Trades: Meta Platforms, Accenture, AbbVie, The Walt Disney Company
AbbVie Submits BLA for Teliso-V in NSCLC With C-Met Protein Overexpression
Express News | Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $214
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Ground Breaking. -- Barrons.com
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Press Release: OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Express News | Abbvie Inc - Tempo-1 Trial Evaluated Two Fixed Doses of Tavapadon
Express News | Abbvie Inc - Phase 3 Tempo-2 Trial Results Expected by End of 2024
Express News | Abbvie Inc - Trial Meets Key Secondary Endpoint in Mds-Updrs Part II Score
Express News | Abbvie: Tavapadon Met Primary Endpoint in Pivotal Phase 3
Express News | Abbvie and Spinup Foster Canadian Life Sciences Innovation With the Launch of the Abbvie Biotech Innovators Award